If you have some cash to put to work, you'll want to take a look at these three companies from the tech, drug, and industrial sectors.
News & Analysis: BioMarin Pharmaceutical
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Global Payments and Total Systems Services announced they plan to merge, and BioMarin reported results from a gene therapy trial.
There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.
Despite the biotech's move into gene therapy, its bread and butter are still paying the bills.
BMRN earnings call for the period ending March 31, 2019.
BioMarin, Waste Management, and Walmart are three top defensive picks worth buying now.
Lumpy sales hurt the orphan-drug maker's fourth quarter, but overall growth is still on track.
Roche's big step into the gene-editing space will spark interest for these two stocks.
BMRN earnings call for the period ending December 31, 2018.